---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-26-000046"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2026-08-04T20:16:02+00:00"
generated_at: "2026-08-04T20:17:43.571805+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q2 revenue flat at $651M; announces restructuring plan with $80-90M charges

## Summary
- Q2 net sales $651.0M flat YoY; GAAP diluted EPS $13.85, non-GAAP diluted EPS $2.62.
- Clinical Diagnostics grew; Life Science soft but digital PCR revenue up >20%.
- Restructuring plan initiated July 31, 2026; pre-tax charges estimated $80-90M, primarily severance and facility closures.
- Plan expected substantially complete by end of FY2027; includes position eliminations and function consolidation.
- Generated $98.7M operating cash flow; repurchased ~$32M shares; full-year outlook reaffirmed.

## SEC filing metadata
- accession: 0000012208-26-000046
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2026-08-04T20:16:02+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220826000046/0000012208-26-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220826000046/bio-20260731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-26-000046
- JSON: https://secwatch.observer/filing/0000012208-26-000046.json
- Plain text: https://secwatch.observer/filing/0000012208-26-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.